Nektar Therapeutics ( NKTR)

Drug: NKTR-102

Abstract No. 5013

Indication: ovarian cancer

Clinical Trial: Phase II study of NKTR-102 in women with platinum-resistant/refractory ovarian cancer.

Presentation Time: Sunday, June 6. Oral session.

Notes: Nektar announced top-line results from this study in early March.

If you liked this article you might like

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

Celldex Therapeutics (CLDX) Stock Up on Q2 Results

Celldex Therapeutics (CLDX) Is Strong On High Volume Today